Cancers of kidney (mostly renal cell carcinoma) appear to require VHL mutation along with two other genetic alterations that may include EGFR mutation, overexpression of genes associated with cellular adhesion molecules (e.g. E-cadherin) and matrix regulatory proteins (e.g. MMPs, bFGF, VEGF) or rarely p53 [20]. The gene discussed is FGF2; the disease is kidney cancer.